Novo Nordisk (NVO) Revenue (2014 - 2026)
Novo Nordisk (NVO) revenue from Dec 31, 2014 to Mar 31, 2026. The TTM Novo Nordisk (NVO) revenue is $51B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Revenue
Quarterly Revenue
Novo Nordisk (NVO) Revenue CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +17.56% |
| 3 Years TTM | +24.65% |
| 5 Years TTM | +20.75% |
| 10 Years TTM | +12.08% |
| All Time TTM | +12.14% |
Annual Revenue change of Novo Nordisk (NVO)
| Year | Revenue | Change |
|---|---|---|
| 2026 | $15B | -69.19% |
| 2025 | $49B | +20.51% |
| 2024 | $40B | +17.25% |
| 2023 | $34B | +35.05% |
| 2022 | $25B | +18.26% |
| 2021 | $22B | +3.31% |
| 2020 | $21B | +13.78% |
| 2019 | $18B | +6.70% |
| 2018 | $17B | -4.59% |
| 2017 | $18B | +13.75% |
| 2016 | $16B | +0.74% |
| 2015 | $16B | +8.77% |
| 2014 | $14B | N/A |
Comparison Novo Nordisk (NVO) five years revenue CAGR with competitors
Novo Nordisk (NVO) five years revenue CAGR is 20.75%.
| Ticker | Name | five years Revenue CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 23.17% | +11.68% |
| AZN | Astrazeneca plc | 16.99% | -18.13% |
| MRK | Merck & Co Inc | 10.41% | -49.84% |
| AMGN | AMGEN Inc | 8.14% | -60.75% |
| PFE | Pfizer Inc | 6.56% | -68.39% |
| GRFS | Grifols SA | 5.39% | -74.00% |
| SNY | Sanofi | 5.03% | -75.77% |
| ABBV | Abbvie Inc | 4.59% | -77.88% |
| GILD | Gilead Sciences Inc | 3.07% | -85.20% |
| JNJ | Johnson & Johnson | 2.73% | -86.83% |
| BMY | Bristol-Myers Squibb Company | 2.52% | -87.86% |
| GSK | GSK Plc | 0.63% | -96.95% |